LSV Asset Management
PTCT icon

LSV Asset Management’s PTC Therapeutics PTCT Stock Holding History

LSV Asset Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57K Sell
700
-2,000
-74% -$144K ﹤0.01% 869
2026
Q1 		$184K Hold
2,700
– – ﹤0.01% 797
2025
Q4 		$205K Hold
2,700
– – ﹤0.01% 786
2025
Q3 		$166K Buy
+2,700
New +$141K ﹤0.01% 809

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

LSV Asset Management's PTCT Position: Q2 2026 in Review

LSV Asset Management reduced its PTC Therapeutics (PTCT) stake by 74% in Q2 2026, selling an estimated $144K and leaving 700 shares worth $57K. The position accounts for ﹤0.01% of the portfolio, ranked #869.

LSV Asset Management first reported a position in PTCT in Q3 2025 and has held it in 4 quarters since. The position peaked at $205K in Q4 2025. 162 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • LSV Asset Management held 700 shares of PTC Therapeutics worth $57K as of Q2 2026.
  • LSV Asset Management sold 2,000 PTC Therapeutics shares in Q2 2026, an estimated $144K.
  • PTC Therapeutics made up ﹤0.01% of LSV Asset Management's portfolio in Q2 2026, its #869 holding.
  • LSV Asset Management first reported a position in PTC Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • LSV Asset Management's PTC Therapeutics position peaked at $205K in Q4 2025.
  • 162 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on LSV Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.